The Valley Desk

Clinical trial reportJournal for immunotherapy of cancerPublished

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal for immunotherapy of cancer
Published
Subject terms
Lymphocytes, Tumor-Infiltrating; Humans; Melanoma; Skin Neoplasms; Immunotherapy, Adoptive; Immune Checkpoint Inhibitors; Immunotherapy; Immunotherapy, adoptive; Lymphocytes, Tumor-infiltrating; Clinical Trials, Phase Ii As Topic
PubMed ID
36600653
PubMed Central ID
PMC9748991
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal